Globus Medical (GMED) Competitors

$84.84 +0.03 (+0.03%)

Closing price 05/22/2026 03:59 PM Eastern

Extended Trading

$84.90 +0.07 (+0.08%)

As of 05/22/2026 07:59 PM Eastern

GMED vs. BDX, RMD, DXCM, STE, and PODD

Should you buy Globus Medical stock or one of its competitors? MarketBeat compares Globus Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Globus Medical include Becton, Dickinson and Company (BDX), ResMed (RMD), DexCom (DXCM), STERIS (STE), and Insulet (PODD). These companies are all part of the "health care equipment" industry.

How does Globus Medical compare to Becton, Dickinson and Company?

Becton, Dickinson and Company (NYSE:BDX) and Globus Medical (NYSE:GMED) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

Becton, Dickinson and Company has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Becton, Dickinson and Company	$21.84B	1.86	$1.68B	$3.95	37.41
Globus Medical	$2.94B	3.92	$537.87M	$4.30	19.73

Globus Medical has a net margin of 18.92% compared to Becton, Dickinson and Company's net margin of 5.33%. Becton, Dickinson and Company's return on equity of 15.37% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Becton, Dickinson and Company	5.33%	15.37%	7.11%
Globus Medical	18.92%	13.46%	11.65%

Becton, Dickinson and Company has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, Globus Medical has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

Becton, Dickinson and Company presently has a consensus target price of $184.86, indicating a potential upside of 25.11%. Globus Medical has a consensus target price of $106.36, indicating a potential upside of 25.37%. Given Globus Medical's stronger consensus rating and higher possible upside, analysts clearly believe Globus Medical is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Becton, Dickinson and Company	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.38
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.81

In the previous week, Globus Medical had 1 more articles in the media than Becton, Dickinson and Company. MarketBeat recorded 17 mentions for Globus Medical and 16 mentions for Becton, Dickinson and Company. Becton, Dickinson and Company's average media sentiment score of 1.00 beat Globus Medical's score of 0.70 indicating that Becton, Dickinson and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Becton, Dickinson and Company	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Globus Medical	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

87.0% of Becton, Dickinson and Company shares are held by institutional investors. Comparatively, 95.2% of Globus Medical shares are held by institutional investors. 0.4% of Becton, Dickinson and Company shares are held by insiders. Comparatively, 18.4% of Globus Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Globus Medical beats Becton, Dickinson and Company on 12 of the 17 factors compared between the two stocks.

How does Globus Medical compare to ResMed?

Globus Medical (NYSE:GMED) and ResMed (NYSE:RMD) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

ResMed has a net margin of 27.44% compared to Globus Medical's net margin of 18.92%. ResMed's return on equity of 25.35% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	18.92%	13.46%	11.65%
ResMed	27.44%	25.35%	18.69%

In the previous week, Globus Medical had 4 more articles in the media than ResMed. MarketBeat recorded 17 mentions for Globus Medical and 13 mentions for ResMed. ResMed's average media sentiment score of 0.81 beat Globus Medical's score of 0.70 indicating that ResMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
ResMed	8 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.2% of Globus Medical shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 18.4% of Globus Medical shares are held by insiders. Comparatively, 0.7% of ResMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Globus Medical presently has a consensus target price of $106.36, suggesting a potential upside of 25.37%. ResMed has a consensus target price of $286.18, suggesting a potential upside of 37.56%. Given ResMed's higher possible upside, analysts plainly believe ResMed is more favorable than Globus Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.81
ResMed	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.73

Globus Medical has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.Comparatively, ResMed has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

ResMed has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.92	$537.87M	$4.30	19.73
ResMed	$5.15B	5.89	$1.40B	$10.37	20.06

Summary

ResMed beats Globus Medical on 10 of the 16 factors compared between the two stocks.

How does Globus Medical compare to DexCom?

Globus Medical (NYSE:GMED) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

DexCom has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.92	$537.87M	$4.30	19.73
DexCom	$4.66B	5.97	$836.30M	$2.34	30.81

Globus Medical currently has a consensus target price of $106.36, indicating a potential upside of 25.37%. DexCom has a consensus target price of $82.21, indicating a potential upside of 14.02%. Given Globus Medical's higher possible upside, equities research analysts clearly believe Globus Medical is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.81
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92

DexCom has a net margin of 19.31% compared to Globus Medical's net margin of 18.92%. DexCom's return on equity of 33.33% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	18.92%	13.46%	11.65%
DexCom	19.31%	33.33%	13.19%

95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 18.4% of Globus Medical shares are owned by company insiders. Comparatively, 0.3% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, DexCom had 8 more articles in the media than Globus Medical. MarketBeat recorded 25 mentions for DexCom and 17 mentions for Globus Medical. DexCom's average media sentiment score of 0.77 beat Globus Medical's score of 0.70 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
DexCom	16 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Globus Medical has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, DexCom has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

Summary

DexCom beats Globus Medical on 14 of the 17 factors compared between the two stocks.

How does Globus Medical compare to STERIS?

Globus Medical (NYSE:GMED) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

In the previous week, Globus Medical had 13 more articles in the media than STERIS. MarketBeat recorded 17 mentions for Globus Medical and 4 mentions for STERIS. Globus Medical's average media sentiment score of 0.70 beat STERIS's score of 0.50 indicating that Globus Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
STERIS	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Globus Medical has a net margin of 18.92% compared to STERIS's net margin of 13.18%. STERIS's return on equity of 14.15% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	18.92%	13.46%	11.65%
STERIS	13.18%	14.15%	9.52%

STERIS has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.92	$537.87M	$4.30	19.73
STERIS	$5.94B	3.58	$782.30M	$7.93	27.32

Globus Medical has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, STERIS has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Globus Medical presently has a consensus price target of $106.36, indicating a potential upside of 25.37%. STERIS has a consensus price target of $274.25, indicating a potential upside of 26.57%. Given STERIS's higher probable upside, analysts plainly believe STERIS is more favorable than Globus Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.81
STERIS	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 18.4% of Globus Medical shares are owned by company insiders. Comparatively, 1.1% of STERIS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Globus Medical beats STERIS on 11 of the 17 factors compared between the two stocks.

How does Globus Medical compare to Insulet?

Insulet (NASDAQ:PODD) and Globus Medical (NYSE:GMED) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

Insulet has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Globus Medical has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

In the previous week, Globus Medical had 6 more articles in the media than Insulet. MarketBeat recorded 17 mentions for Globus Medical and 11 mentions for Insulet. Globus Medical's average media sentiment score of 0.70 beat Insulet's score of 0.21 indicating that Globus Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	0 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Globus Medical	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Insulet presently has a consensus target price of $254.96, suggesting a potential upside of 64.63%. Globus Medical has a consensus target price of $106.36, suggesting a potential upside of 25.37%. Given Insulet's higher probable upside, analysts clearly believe Insulet is more favorable than Globus Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	1 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.74
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.81

Globus Medical has higher revenue and earnings than Insulet. Globus Medical is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	3.96	$247.10M	$4.30	36.02
Globus Medical	$2.94B	3.92	$537.87M	$4.30	19.73

Globus Medical has a net margin of 18.92% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	10.44%	26.87%	12.01%
Globus Medical	18.92%	13.46%	11.65%

95.2% of Globus Medical shares are owned by institutional investors. 0.4% of Insulet shares are owned by insiders. Comparatively, 18.4% of Globus Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Globus Medical beats Insulet on 9 of the 16 factors compared between the two stocks.

Get Globus Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMED vs. The Competition

Export

Metric	Globus Medical	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$11.51B	$7.10B	$6.46B	$23.20B
Dividend Yield	N/A	1.68%	2.76%	4.10%
P/E Ratio	19.73	47.45	21.22	30.65
Price / Sales	3.92	73.72	562.28	24.50
Price / Cash	13.50	24.91	43.49	25.12
Price / Book	2.43	6.53	10.31	4.74
Net Income	$537.87M	$158.81M	$3.57B	$1.07B
7 Day Performance	6.31%	3.61%	6.43%	2.36%
1 Month Performance	-10.75%	0.74%	3.57%	1.58%
1 Year Performance	43.80%	3.17%	34.07%	28.42%

Globus Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMED Globus Medical	4.7693 of 5 stars	$84.84 +0.0%	$106.36 +25.4%	+43.8%	$11.51B	$2.94B	19.73	6,000	Analyst Revision
BDX Becton, Dickinson and Company	4.8874 of 5 stars	$142.36 -0.8%	$184.86 +29.9%	-13.8%	$39.53B	$21.84B	36.04	72,000	Positive News
RMD ResMed	4.7997 of 5 stars	$203.97 +1.0%	$286.18 +40.3%	-14.4%	$29.41B	$5.15B	19.67	10,600
DXCM DexCom	4.1889 of 5 stars	$65.09 +5.6%	$82.21 +26.3%	-14.7%	$23.78B	$4.66B	27.82	11,000	High Trading Volume
STE STERIS	4.616 of 5 stars	$213.22 +0.5%	$275.67 +29.3%	-10.9%	$20.80B	$5.94B	26.89	17,787

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GMED) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Globus Medical (GMED) Competitors

GMED vs. BDX, RMD, DXCM, STE, and PODD

How does Globus Medical compare to Becton, Dickinson and Company?

Summary

How does Globus Medical compare to ResMed?

Summary

How does Globus Medical compare to DexCom?

Summary

How does Globus Medical compare to STERIS?

Summary

How does Globus Medical compare to Insulet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMED vs. The Competition

Globus Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Globus Medical (GMED) Competitors

GMED vs. BDX, RMD, DXCM, STE, and PODD

How does Globus Medical compare to Becton, Dickinson and Company?

Which has preferable valuation and earnings, BDX or GMED?

Is BDX or GMED more profitable?

Which has more risk and volatility, BDX or GMED?

Do analysts rate BDX or GMED?

Does the media favor BDX or GMED?

Do insiders and institutionals believe in BDX or GMED?

Summary

How does Globus Medical compare to ResMed?

Is GMED or RMD more profitable?

Does the media refer more to GMED or RMD?

Do insiders & institutionals hold more shares of GMED or RMD?

Do analysts prefer GMED or RMD?

Which has more risk and volatility, GMED or RMD?

Which has higher earnings and valuation, GMED or RMD?

Summary

How does Globus Medical compare to DexCom?

Which has higher valuation and earnings, GMED or DXCM?

Do analysts prefer GMED or DXCM?

Is GMED or DXCM more profitable?

Do institutionals and insiders believe in GMED or DXCM?

Does the media favor GMED or DXCM?

Which has more risk & volatility, GMED or DXCM?

Summary

How does Globus Medical compare to STERIS?

Does the media refer more to GMED or STE?

Is GMED or STE more profitable?

Which has preferable earnings & valuation, GMED or STE?

Which has more volatility & risk, GMED or STE?

Do analysts prefer GMED or STE?

Do institutionals & insiders believe in GMED or STE?

Summary

How does Globus Medical compare to Insulet?

Which has more volatility and risk, PODD or GMED?

Does the media prefer PODD or GMED?

Do analysts prefer PODD or GMED?

Which has preferable valuation & earnings, PODD or GMED?

Is PODD or GMED more profitable?

Do insiders & institutionals have more ownership in PODD or GMED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMED vs. The Competition

Globus Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools